MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Martin van den Bent, Lale Erdem, A Idbaih, Jacob Rooi, Paul Eilers, WGM Spliet, WFA den Dunnen, C Tijssen, P Wesseling, Peter Sillevis Smitt, J.M. Kros, T Gorlia, Pim French

Research output: Contribution to journalArticleAcademicpeer-review

106 Citations (Scopus)


Purpose: The long-term follow-up results from the EORTC-26951 trial showed that the addition of procarbazine, CCNU, and vincristine (PCV) after radiotherapy increases survival in anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA). However, some patients appeared to benefit more from PCV treatment than others. Experimental Design: We conducted genome-wide methylation profiling of 115 samples included in the EORTC-26951 trial and extracted the CpG island hypermethylated phenotype (CIMP) and MGMT promoter methylation (MGMT-STP27) status. Results: We first show that methylation profiling can be conducted on archival tissues with a performance that is similar to snap-frozen tissue samples. We then conducted methylation profiling on EORTC-26951 clinical trial samples. Univariate analysis indicated that CIMP+ or MGMT-STP27 methylated tumors had an improved survival compared with CIMP- and/or MGMT-STP27 unmethylated tumors [median overall survival (OS), 1.05 vs. 6.46 years and 1.06 vs. 3.8 years, both P < 0.0001 for CIMP and MGMT-STP Conclusions: MGMT-STP27 may be used to guide treatment decisions in this tumor type. (C) 2013 AACR.
Original languageUndefined/Unknown
Pages (from-to)5513-5522
Number of pages10
JournalClinical Cancer Research
Issue number19
Publication statusPublished - 2013

Research programs

  • EMC MM-03-24-01
  • EMC MM-03-44-06
  • EMC NIHES-01-66-01

Cite this